US EditionBayer CEO confident firm can cope with Xarelto hit
- Bayer CEO Bill Anderson expressed confidence in managing the sales decline of Xarelto amid Q1 challenges worldwide.
- The decline resulted from generic competition in Europe and Japan and Xarelto's US patent expiry in May 2025.
- Bayer offset losses with strong growth in new products like Nubeqa, Kerendia, and Eylea, while also advancing cost-reduction plans.
- Xarelto sales fell nearly 33% to $633 million in Q1, while Nubeqa rose 78% to $515 million and Eylea grew almost 5%.
- Anderson maintained Bayer's full-year guidance despite expected pharma sales dipping about 1%, citing launch momentum and tariff uncertainty.
10 Articles
10 Articles
Exchange balance sheets: Bayer share according to figures in high noise – "There you can speculate"
Despite uncertainty from US customs policy, Bayer does not look as bad as feared. The share increased by 12 percent in the top. Dietmar Deffner talks about these and other Dax bills with stock market expert Jürgen Schmitt.
Smart weighing boosts Bayer’s production automation - Factory & Handling Solutions
The new supply centre of the agricultural chemical and pharmaceutical company Bayer in Hangzhou integrates weighing technology of Minebea Intec for precise mixing and homogenisation in Zone 2 hazardous areas. Features like smart calibration save time and labour, while seamless system integration ensures scalability. As a division of the Bayer Group, Bayer Crop Science holds a leading position in the global agricultural technology sector. Recentl…
Coverage Details
Bias Distribution
- 33% of the sources lean Left, 33% of the sources are Center, 33% of the sources lean Right
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
